BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 9204956)

  • 1. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal.
    Castellano M; Gabrielli BG; Hussussian CJ; Dracopoli NC; Hayward NK
    J Invest Dermatol; 1997 Jul; 109(1):61-8. PubMed ID: 9204956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional reassessment of P16 variants using a transfection-based assay.
    Walker GJ; Gabrielli BG; Castellano M; Hayward NK
    Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of human tumour suppressor genes by monochromosome transfer: rapid growth-arrest response mapped to 9p21 is mediated solely by the cyclin-D-dependent kinase inhibitor gene, CDKN2A (p16INK4A).
    England NL; Cuthbert AP; Trott DA; Jezzard S; Nobori T; Carson DA; Newbold RF
    Carcinogenesis; 1996 Aug; 17(8):1567-75. PubMed ID: 8761411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo.
    Fujita M; Norris DA; Yagi H; Walsh P; Morelli JG; Weston WL; Terada N; Bennion SD; Robinson W; Lemon M; Maxwell IH; Yohn JJ
    Melanoma Res; 1999 Jun; 9(3):279-91. PubMed ID: 10465584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation.
    Piepkorn M
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):741-5. PubMed ID: 10775848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
    Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
    Cancer Lett; 2002 Jun; 180(2):211-21. PubMed ID: 12175554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line.
    Frost SJ; Simpson DJ; Clayton RN; Farrell WE
    Mol Endocrinol; 1999 Nov; 13(11):1801-10. PubMed ID: 10551774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.
    Sviderskaya EV; Gray-Schopfer VC; Hill SP; Smit NP; Evans-Whipp TJ; Bond J; Hill L; Bataille V; Peters G; Kipling D; Wynford-Thomas D; Bennett DC
    J Natl Cancer Inst; 2003 May; 95(10):723-32. PubMed ID: 12759390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.
    Arap W; Knudsen ES; Wang JY; Cavenee WK; Huang HJ
    Oncogene; 1997 Feb; 14(5):603-9. PubMed ID: 9053859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
    Sherburn TE; Gale JM; Ley RD
    DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.
    Piepkorn M
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):705-22; quiz 723-6. PubMed ID: 10775844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.